BCR and diffuse large B-cell lymphoma: Accordingly, activating mutations of the BCR component CD79B (Y196H) and intracytoplasmic signaling molecule MYD88 (L265P) are a hallmark of the molecularly-defined MCD/C5 subtype within this DLBCL category.